9 results on '"Niezink, Anne G. H."'
Search Results
2. Population-Based External Validation of the EASIX Scores to Predict CAR T-Cell-Related Toxicities
- Author
-
de Boer, Janneke W., primary, Keijzer, Kylie, additional, Pennings, Elise R. A., additional, van Doesum, Jaap A., additional, Spanjaart, Anne M., additional, Jak, Margot, additional, Mutsaers, Pim G. N. J., additional, van Dorp, Suzanne, additional, Vermaat, Joost S. P., additional, van der Poel, Marjolein W. M., additional, van Dijk, Lisanne V., additional, Kersten, Marie José, additional, Niezink, Anne G. H., additional, and van Meerten, Tom, additional
- Published
- 2023
- Full Text
- View/download PDF
3. Inflammatory reactions mimic residual or recurrent lymphoma on [18F]FDG-PET/CT after CD19-directed CAR T-cell therapy
- Author
-
de Boer, Janneke W., primary, Pennings, Elise R. A., additional, Kleinjan, Ankie, additional, van Doesum, Jaap A., additional, Spanjaart, Anne M., additional, Mutsaers, Pim G. N. J., additional, Jak, Margot, additional, van der Poel, Marjolein W. M., additional, Kuipers, Maria T., additional, Adam, Judit A., additional, Diepstra, Arjan, additional, Koens, Lianne, additional, van Dorp, Suzanne, additional, Vermaat, Joost S. P., additional, Niezink, Anne G. H., additional, Kersten, Marie José, additional, and van Meerten, Tom, additional
- Published
- 2023
- Full Text
- View/download PDF
4. The Dutch CAR-T Tumorboard Experience: Population-Based Real-World Data on Patients with Relapsed or Refractory Large B-Cell Lymphoma Referred for CD19-Directed CAR T-Cell Therapy in The Netherlands
- Author
-
Spanjaart, Anne M., primary, Pennings, Elise R. A., additional, Mutsaers, Pim G. N. J., additional, van Dorp, Suzanne, additional, Jak, Margot, additional, van Doesum, Jaap A., additional, de Boer, Janneke W., additional, Niezink, Anne G. H., additional, Kos, Milan, additional, Vermaat, Joost S. P., additional, Sijs-Szabo, Aniko, additional, van der Poel, Marjolein W. M., additional, Nijhof, Inger S., additional, Kuipers, Maria T., additional, Chamuleau, Martine E. D., additional, Lugtenburg, Pieternella J., additional, Doorduijn, Jeanette K., additional, Serroukh, Yasmina I. M., additional, Minnema, Monique C., additional, van Meerten, Tom, additional, and Kersten, Marie José, additional
- Published
- 2023
- Full Text
- View/download PDF
5. Proton and photon radiotherapy in stage III NSCLC: Effects on hematological toxicity and adjuvant immune therapy.
- Author
-
Cortiula F, Hendriks LEL, Wijsman R, Houben R, Steens M, Debakker S, Canters R, Trovò M, Sijtsema NM, Niezink AGH, Unipan M, Urban S, Michelotti A, Dursun S, Bootsma G, Hattu D, Nuyttens JJ, Moretti E, Taasti VT, and De Ruysscher D
- Subjects
- Humans, Male, Aged, Female, Protons, Positron Emission Tomography Computed Tomography, Retrospective Studies, Radiotherapy Dosage, Radiotherapy Planning, Computer-Assisted methods, Carcinoma, Non-Small-Cell Lung therapy, Proton Therapy adverse effects, Proton Therapy methods, Lung Neoplasms therapy, Lung Neoplasms etiology, Lymphopenia etiology, Anemia etiology, Radiotherapy, Intensity-Modulated adverse effects, Radiotherapy, Intensity-Modulated methods
- Abstract
Background and Purpose: Concurrent chemo-radiotherapy (CCRT) followed by adjuvant durvalumab is standard-of-care for fit patients with unresectable stage III NSCLC. Intensity modulated proton therapy (IMPT) results in different doses to organs than intensity modulated photon therapy (IMRT). We investigated whether IMPT compared to IMRT reduce hematological toxicity and whether it affects durvalumab treatment., Materials and Methods: Prospectively collected series of consecutive patients with stage III NSCLC receiving CCRT between 06.16 and 12.22 (staged with FDG-PET-CT and brain imaging) were retrospectively analyzed. The primary endpoint was the incidence of lymphopenia grade ≥ 3 in IMPT vs IMRT treated patients., Results: 271 patients were enrolled (IMPT: n = 71, IMRT: n = 200) in four centers. All patients received platinum-based chemotherapy. Median age: 66 years, 58 % were male, 36 % had squamous NSCLC. The incidence of lymphopenia grade ≥ 3 during CCRT was 67 % and 47 % in the IMRT and IMPT group, respectively (OR 2.2, 95 % CI: 1.0-4.9, P = 0.03). The incidence of anemia grade ≥ 3 during CCRT was 26 % and 9 % in the IMRT and IMPT group respectively (OR = 4.9, 95 % CI: 1.9-12.6, P = 0.001). IMPT was associated with a lower rate of Performance Status (PS) ≥ 2 at day 21 and 42 after CCRT (13 % vs. 26 %, P = 0.04, and 24 % vs. 39 %, P = 0.02). Patients treated with IMPT had a higher probability of receiving adjuvant durvalumab (74 % vs. 52 %, OR 0.35, 95 % CI: 0.16-0.79, P = 0.01)., Conclusion: IMPT was associated with a lower incidence of severe lymphopenia and anemia, better PS after CCRT and a higher probability of receiving adjuvant durvalumab., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
6. External validation of NTCP-models for radiation pneumonitis in lung cancer patients treated with chemoradiotherapy.
- Author
-
Niezink AGH, van der Schaaf A, Wijsman R, Chouvalova O, van der Wekken AJ, Rutgers SR, Pieterman RM, van Putten JWG, de Hosson SM, van der Leest AHD, Ubbels JF, Woltman-van Iersel M, Widder J, Langendijk JA, and Muijs CT
- Subjects
- Humans, Prospective Studies, Probability, Chemoradiotherapy adverse effects, Radiotherapy Dosage, Radiation Pneumonitis diagnosis, Radiation Pneumonitis epidemiology, Radiation Pneumonitis etiology, Lung Neoplasms radiotherapy
- Abstract
Purpose: Normal tissue complication probability (NTCP) models can be used to estimate the risk of radiation pneumonitis (RP). The aim of this study was to externally validate the most frequently used prediction models for RP, i.e., the QUANTEC and APPELT models, in a large cohort of lung cancer patients treated with IMRT or VMAT. [1-2] METHODS AND MATERIALS: This prospective cohort study, included lung cancer patients treated between 2013 and 2018. A closed testing procedure was performed to test the need for model updating. To improve model performance, modification or removal of variables was considered. Performance measures included tests for goodness of fit, discrimination, and calibration., Results: In this cohort of 612 patients, the incidence of RP ≥ grade 2 was 14.5%. For the QUANTEC-model, recalibration was recommended which resulted in a revised intercept and adjusted regression coefficient (from 0.126 to 0.224) of the mean lung dose (MLD),. The APPELT-model needed revision including model updating with modification and elimination of variables. After revision, the New RP-model included the following predictors (and regression coefficients): MLD (B = 0.250), age (B = 0.049, and smoking status (B = 0.902). The discrimination of the updated APPELT-model was higher compared to the recalibrated QUANTEC-model (AUC: 0.79 vs. 0.73)., Conclusions: This study demonstrated that both the QUANTEC- and APPELT-model needed revision. Next to changes of the intercept and regression coefficients, the APPELT model improved further by model updating and performed better than the recalibrated QUANTEC model. This New RP-model is widely applicable containing non-tumour site specific variables, which can easily be collected., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
7. Semi-automated 18 F-FDG PET segmentation methods for tumor volume determination in Non-Hodgkin lymphoma patients: a literature review, implementation and multi-threshold evaluation.
- Author
-
Keijzer K, Niezink AGH, de Boer JW, van Doesum JA, Noordzij W, van Meerten T, and van Dijk LV
- Abstract
In the treatment of Non-Hodgkin lymphoma (NHL), multiple therapeutic options are available. Improving outcome predictions are essential to optimize treatment. The metabolic active tumor volume (MATV) has shown to be a prognostic factor in NHL. It is usually retrieved using semi-automated thresholding methods based on standardized uptake values (SUV), calculated from
18 F-Fluorodeoxyglucose Positron Emission Tomography (18 F-FDG PET) images. However, there is currently no consensus method for NHL. The aim of this study was to review literature on different segmentation methods used, and to evaluate selected methods by using an in house created software tool. A software tool, MU ltiple S UV T hreshold (MUST)-segmenter was developed where tumor locations are identified by placing seed-points on the PET images, followed by subsequent region growing. Based on a literature review, 9 SUV thresholding methods were selected and MATVs were extracted. The MUST-segmenter was utilized in a cohort of 68 patients with NHL. Differences in MATVs were assessed with paired t-tests, and correlations and distributions figures. High variability and significant differences between the MATVs based on different segmentation methods ( p < 0.05) were observed in the NHL patients. Median MATVs ranged from 35 to 211 cc. No consensus for determining MATV is available based on the literature. Using the MUST-segmenter with 9 selected SUV thresholding methods, we demonstrated a large and significant variation in MATVs. Identifying the most optimal segmentation method for patients with NHL is essential to further improve predictions of toxicity, response, and treatment outcomes, which can be facilitated by the MUST-segmenter., Competing Interests: The Department of Radiation Oncology has research collaborations with Elekta, IBA, RaySearch, Siemens, Mirada, Bergoz Instrumentation and Medical Data Works, Genentech. Dr. van Meerten reported research grants from Genentech, Celgene/BMS; personal fees from Kite/Gilead and Janssen (advisory boards); and honoraria from Kite/Gilead and Celgene/BMS (speaker fees) outside the submitted work., (© 2023 The Authors.)- Published
- 2023
- Full Text
- View/download PDF
8. Robustness assessment of clinical adaptive proton and photon radiotherapy for oesophageal cancer in the model-based approach.
- Author
-
Visser S, O Ribeiro C, Dieters M, Mul VE, Niezink AGH, van der Schaaf A, Knopf AC, Langendijk JA, Korevaar EW, Both S, and Muijs CT
- Subjects
- Humans, Radiotherapy Planning, Computer-Assisted methods, Radiotherapy Dosage, Protons, Organs at Risk, Radiotherapy, Intensity-Modulated methods, Proton Therapy methods, Esophageal Neoplasms radiotherapy
- Abstract
Purpose: In the Netherlands, oesophageal cancer (EC) patients are selected for intensity modulated proton therapy (IMPT) using the expected normal tissue complication probability reduction (ΔNTCP) when treating with IMPT compared to volumetric modulated arc therapy (VMAT). In this study, we evaluate the robustness of the first EC patients treated with IMPT in our clinic in terms of target and organs-at-risk (OAR) dose with corresponding NTCP, as compared to VMAT., Materials and Methods: For 20 consecutive EC patients, clinical IMPT and VMAT plans were created on the average planning 4DCT. Both plans were robustly evaluated on weekly repeated 4DCTs and if target coverage degraded, replanning was performed. Target coverage was evaluated for complete treatment trajectories with and without replanning. The planned and accumulated mean lung dose (MLD) and mean heart dose (MHD) were additionally evaluated and translated into NTCP., Results: Replanning in the clinic was performed more often for IMPT (15x) than would have been needed for VMAT (8x) (p = 0.11). Both adaptive treatments would have resulted in adequate accumulated target dose coverage. Replanning in the first week of treatment had most clinical impact, as anatomical changes resulting in insufficient accumulated target coverage were already observed at this stage. No differences were found in MLD between the planned dose and the accumulated dose. Accumulated MHD differed from the planned dose (p < 0.001), but since these differences were similar for VMAT and IMPT (1.0 and 1.5 Gy, respectively), the ΔNTCP remained unchanged., Conclusion: Following an adaptive clinical workflow, adequate target dose coverage and stable OAR doses with corresponding NTCPs was assured for both IMPT and VMAT., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2022 The Author(s). Published by Elsevier B.V. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
9. [New treatment for patients with therapy-resistant lymphoma: CD19-targeted chimeric antigen receptor (CAR) T-cell therapy].
- Author
-
van Doesum JA, Niezink AGH, and van Meerten T
- Subjects
- Antigens, CD19, Cell- and Tissue-Based Therapy, Humans, Immunotherapy, Adoptive, Lymphoma, Large B-Cell, Diffuse, Receptors, Chimeric Antigen
- Abstract
The prognosis of patients with diffuse large B-cell lymphoma a primary refractory disease or relapsed within 12 months after autologous hematopoietic cell transplantation is poor with a median survival of only 6 months. With the new CD19-directed CAR T-cell therapy, 40% of the patients still achieve a long-term remission. However, this new treatment does bring new challenges such as bridging the time during the CAR T-cell product time, and recognition of treatment-related side effects such as cytokine release syndrome or neurotoxicity. Therefore, treatment by a dedicated, multidisciplinary team is necessary. Future research will focus on extending CAR T-cell therapy to other diseases and improve treatment in non-responsiveness or resistance to CAR-T cell therapy.
- Published
- 2021
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.